News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2023-12-07 5:4:42 am Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma BusinessWire
2023-11-23 6:55:14 am Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade Zacks
2023-11-12 4:6:28 am David Johnson Bought 232% More Shares In Aura Biosciences Simply Wall St.
2023-11-09 1:5:0 pm Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Business Wire
2023-11-08 4:0:0 am Aura Biosciences to Participate in Upcoming Investor Conferences Business Wire
2023-11-06 7:2:0 pm Aura Biosciences Announces Pricing of Public Offering of Common Stock Business Wire
2023-11-06 1:8:0 pm Aura Biosciences Announces Proposed Public Offering of Common Stock Business Wire
2023-11-06 12:0:0 pm Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma Business Wire
2023-10-31 1:5:0 pm Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 Business Wire
   

Please consider a small donation if you think this website provides you with relevant information